NCT03659461View on ClinicalTrials.gov

Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus

NACompletedINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

January 31, 2020

Conditions

Type 2 Diabetes MellitusPreDiabetes

Interventions

DRUG

Sitagliptin

oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.

Trial Locations (1)

81100

Hospital Sultan Ismail, Johor Bahru

All Listed Sponsors

lead

National University of Malaysia

OTHER

NCT03659461 - Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter